Bullets:
China draws tens of thousands of patients from across the world, who access cutting-edge drugs and therapies at low cost.
The US Food and Drug Administration allows for American patients to buy medicines abroad, and bring them back to the US, in certain very limited circumstances.
Western pharma giants have discovered a massive new profit center, in buying global distribution rights from top Chinese labs, then aggressively marking up the price for patients in North America and Europe.
Closing scene, Liuye Lake, Chengde
Resources and links:
As Politicians Argue About China, US Patients Find Cutting-Edge Treatment There
https://kffhealthnews.org/health-industry/china-cancer-drugs-foreign-travel-pharma-biotech-fda-regulation-clinical-trials/
Washington Post, US Patients fly to China for life-saving cancer drugs
https://www.washingtonpost.com/health/2026/10/20/us-cancer-patients-need-lifesaving-drugs-some-have-get-them-china/
FDA, Regulations Governing Personal Importation
https://www.fda.gov/industry/import-basics/personal-importation
Chinese cancer drug on sale in US after Americans travel to buy it: ‘saved my mom’s life’
https://www.scmp.com/news/us/article/3371835/china-made-cancer-drug-go-sale-us-after-americans-travel-buy-it
Sunvozertinib (Zegfrovy) Launches in US for Previously Treated EGFR Exon 20 Insertion NSCLC
https://trial.medpath.com/news/sunvozertinib-zegfrovy-launches-in-us-for-previously-treated-egfr-exon-20-insertion-nsclc
Zegfrovy (Sunvozertinib) | NSCLC | HongKong DengYue Med
https://dengyuemed.com/product/zegfrovy-sunvozertinib-nsclc/
AstraZeneca Secures ZEGFROVY Rights in Up to $1.5B Deal
https://trial.medpath.com/news/astrazeneca-secures-zegfrovy-rights-in-up-to-1-5b-deal
AstraZeneca Made a $1.5 Billion Lung Cancer Bet, but Can Zegfrovy Strengthen its Oncology Growth?
https://finance.yahoo.com/healthcare/articles/astrazeneca-made-1-5-billion-193855181.html
Sunvozertinib in EGFR Exon 20 Insertion NSCLC: Approved but Not Available – Practical Dose Selection Considerations and Real-World Access Challenges
https://www.dovepress.com/sunvozertinib-in-egfr-exon-20-insertion-nsclc-approved-but-not-availab-peer-reviewed-fulltext-article-LCTT
ZEGFROVY® (sunvozertinib) now available in the US for patients with previously treated non-small cell lung cancer with EGFR exon 20 insertion mutations
https://www.stocktitan.net/news/AZN/zegfrovy-sunvozertinib-now-available-in-the-us-for-patients-with-sncw2bb9ifkm.html
Dizal Pharma, company page
https://www.dizalpharma.com/
Dizal to Present Emerging Data on ZEGFROVY® in Non-Small Cell Lung Cancer at WCLC 2026
https://www.prnewswire.com/news-releases/dizal-to-present-emerging-data-on-zegfrovy-in-non-small-cell-lung-cancer-at-wclc-2026-302857202.html
Inside China Business, Are we measuring China’s GDP wrong?
From Inside China / Business via This RSS Feed.